Patient Assistance & Copay Programs for Rubraca Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines and copay programs to low income or uninsured and under-insured people who meet specific guidelines. Eligibility requirements vary for each program.
Full Answer
Is there a generic for Rubraca?
Has a generic version of Rubraca been approved? No. There is currently no therapeutically equivalent version of Rubraca available in the United States.
What company makes Rubraca?
Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration (FDA) for Rubraca (rucaparib) as a monotherapy for BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC) adult patients.
How long can you take Rubraca?
You usually start taking rucaparib 2 months after the last dose of platinum chemotherapy. You take it for as long as it is working and the side effects aren't too bad.
Is rucaparib FDA approved?
The approvals are for the drugs olaparib (Lynparza) and rucaparib (Rubraca). They cover the use of the drugs in men whose prostate cancer has spread, or metastasized, and whose disease has stopped responding to standard hormone treatments, often called castration-resistant disease.
Is Rubraca a good drug?
Effectiveness for ovarian cancer Clinical studies have shown that Rubraca is an effective treatment for ovarian cancer. One clinical study looked at adults whose ovarian cancer had returned and was responding to platinum-based chemotherapy. Rubraca was compared with a placebo (treatment with no active drug).
Who manufactures Niraparib?
In October 2019, GlaxoSmithKline launched niraparib for an expanded indication for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients, who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency.
What is the brand name for rucaparib?
Mumbai, 27 May 2021: BDR Pharmaceutical launched BDPARIB (RUCAPARIB) to treat advanced ovarian and prostate cancers today. BDPARIB is the first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the market.
Who makes olaparib?
AstraZeneca strives to make LYNPARZA affordable by targeting a $0 co-pay for all eligible patients. This is based on commercially insured patients.
How to contact Rubraca?
Rubraca Connections can support you in getting Rubraca and help you in navigating financial assistance. For more information, call 1-844-779-7707, Monday through Friday, 8 am to 8 pm ET, or visit www.RubracaConnections.com
What are the side effects of Rubraca?
The most common side effects for men in Rubraca clinical studies were weakness/fatigue, nausea, decreased red blood cell count, changes in liver function tests, decreased appetite, constipation, rash, decreased platelet count, vomiting, and diarrhea.
What is Rubraca used for?
Rubraca ® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):
What Warnings should I know about Rubraca?
Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called A cute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.
What other important information should I know about Rubraca?
Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.
What is Rubraca Connections?
Rubraca Connections is a personalized support program with live dedicated Access Specialists to answer your questions about starting, affording, and continuing your Rubraca
How long after Rubraca can you donate sperm?
If you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of Rubraca. Do not donate sperm during use and for 3 months after the last dose of Rubraca.
How to contact Rubraca?from rubraca.com
Rubraca Connections can support you in getting Rubraca and help you in navigating financial assistance. For more information, call 1-844-779-7707, Monday through Friday, 8 am to 8 pm ET, or visit www.RubracaConnections.com
What are the side effects of Rubraca?from rubraca.com
The most common side effects for men in Rubraca clinical studies were weakness/fatigue, nausea, decreased red blood cell count, changes in liver function tests, decreased appetite, constipation, rash, decreased platelet count, vomiting, and diarrhea.
What is Rubraca used for?from rubraca.com
Rubraca ® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):
What Warnings should I know about Rubraca?from rubraca.com
Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called A cute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.
What other important information should I know about Rubraca?from rubraca.com
Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.
What other medications might interact with Rubraca?from rubraca.com
Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How long after Rubraca can you breastfeed?from rubraca.com
You are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.
What is the drug class of Rubraca?
Rubraca (rucaparib) is a member of the PARP inhibitors drug class and is commonly used for Ovarian Cancer, and Prostate Cancer.
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Is Rubraca a generic?
Rubraca is available as a brand name drug only, a generic version is not yet available. For more information, read about generic Rubraca availability . This Rubraca price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
What is Rubraca used for?
Rubraca is indicated: for the maintenance treatment of adult women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. for the treatment of adult women with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, ...
What is mCRPC treatment?
for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
How long after Rubraca can you breastfeed?
Because of the potential for serious adverse reactions in breast-fed children from Rubraca, advise lactating women not to breastfeed during treatment with Rubraca and for 2 weeks after the last dose. Please see full Prescribing Information for additional Important Safety Information.
Can you give a pregnant woman rubraca?
Based on its mechanism of action and findings from animal studies, Rubraca can cause fetal harm when administered to a pregnant woman. Apprise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Rubraca. For males on Rubraca treatment who have female partners of reproductive potential or who are pregnant, effective contraception should be used during treatment and for 3 months following the last dose of Rubraca.
Is Rubraca a fatal drug?
Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) occur in patients treated with Rubraca, and are potentially fatal adverse reactions. In 1146 treated patients, MDS/AML occurred in 20 patients (1.7%), including those in long term follow-up. Of these, 8 occurred during treatment or during the 28 day safety follow-up (0.7%). The duration of Rubraca treatment prior to the diagnosis of MDS/AML ranged from 1 month to approximately 53 months. The cases were typical of secondary MDS/cancer therapy-related AML; in all cases, patients had received previous platinum-containing regimens and/or other DNA damaging agents. In TRITON2, MDS/AML was not observed in patients with mCRPC (n=209) regardless of homologous recombination deficiency (HRD) mutation.
What is rucaparib used for?from drugs.com
Rucaparib is also used to treat prostate cancer with an abnormal BRCA gene. Rucaparib is given for this condition when the cancer has spread to other parts of the body and surgery or other cancer treatments did not work or have stopped working.
What other drugs will affect rucaparib?from drugs.com
Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.
What is Rubraca?from drugs.com
Rubraca ( rucaparib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
What Warnings should I know about Rubraca?from rubraca.com
Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called A cute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.
How should I take Rubraca?from drugs.com
Take Rubraca exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.
What are the side effects of Rubraca?from rubraca.com
The most common side effects for women in the Rubraca clinical studies were nausea, tiredness/weakness, stomach pain, rash, altered taste, decrease in hemoglobin, abnormal liver or kidney function blood tests, constipation, vomiting, diarrhea, decrease in platelets, upper respiratory tract infection, mouth sores, decreased appetite, shortness of breath, and decrease in white blood cell count.
What other medications might interact with Rubraca?from rubraca.com
Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Side Effects
In clinical studies, the most commonly reported rucaparib (Rubraca®) side effects are shown here. Side effects sometimes have percentage ranges [example 75 – 77%] because they differed between clinical studies:
Monitoring
Labs (blood tests) may be checked before treatment starts, then monthly throughout treatment. The frequency of labs may depend on how well you are tolerating treatment with rucaparib.
Questions to Ask Your..
A better understanding of your treatments will allow you to ask more questions of your healthcare team. We then hope that with the answers, you will get better results and have greater satisfaction with your care. Because we know it's not always easy to know what questions to ask, we've tried to make it easy for you!
Patient Assistance & Co-payment Coverage
Patients under the age of 65 years, or those with private insurance plans: If you have insurance and are looking for patient assistance or copay assistance for Rucaparib (Rubraca®), we have provided links that may help.
Emotional Wellness
What is Emotional Wellness? Emotional wellness is having a positive outlook balanced with a realistic understanding of current life events. This requires both an awareness and acceptance of your emotions. It is with this knowledge that you can develop a plan to take the necessary actions to positively impact your life.
What is Rubraca used for?from fda.gov
On April 6, 2018, the Food and Drug Administration approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
What is a tBRCA test?from fda.gov
Tumor tissue samples were examined with a next-generation sequencing assay to determine whether DNA contained a deleterious somatic or germline BRCA mutation (tBRCA). This test was also used to determine the percentage of genomic loss of heterozygosity (LOH). Positive homologous recombination deficiency (HRD) status was defined as tBRCA-positive and/or LOH high. Three patient outcomes analyses were performed on the following groups: all patients, HRD subgroup, and tBRCA subgroup.
Is rucaparib approved for CDxBRCA?from fda.gov
Approval of rucaparib and the FoundationFo cus CDxBRCA test was based on data from two multicenter, single-arm, open label clinical trials that evaluated the efficacy of rucaparib in 106 patients with advanced ovarian cancer who had progressed after treatment with two or more prior chemotherapies. During enrollment, BRCA1/2 status was determined using either local germline BRCA test results or a Foundation Medicine clinical trial assay. Formalin-fixed paraffin-embedded tumor tissue samples were collected for testing with the companion diagnostic. Tumor BRCA mutation status was verified retrospectively in 96% (64/67) of the patients for whom a tumor tissue sample was available by the FoundationFocus CDxBRCA test.
Is rucaparib safe for ovarian cancer?from fda.gov
The safety of rucaparib was evaluated in 377 patients with advanced ovarian cancer. The most common adverse reactions (greater than or equal to 20%) experienced by patients were nausea, fatigue (including asthenia), vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea. Adverse reactions led to dose discontinuation in 10% of patients, most frequently from fatigue/asthenia (2%).
